To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?

ABSTRACT:

Introduction

Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs.

Methods

A qualitative study was conducted in Nigeria and Burkina Faso and comprised in-depth interviews (n = 68) and focus group discussions (n = 11) with key actor groups in the innovation system of antimalarial therapies.

Res

SUBMITTER: de Haan F 

PROVIDER: S-EPMC8407563 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature